Corticosteroid Therapy in IgA Nephropathy
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
The benefits and risks of steroids for the treatment of IgA nephropathy remain uncertain. We systematically searched MEDLINE, EMBASE, and the Cochrane Library for randomized, controlled trials of corticosteroid therapy for IgA nephropathy published between 1966 and March 2011. We identified nine relevant trials that included 536 patients who had urinary protein excretion >1 g/d and normal renal function. Forty-six (8.6%) of these patients developed a kidney failure event, defined as doubling of the serum creatinine/halving of the GFR or ESRD. Overall, steroid therapy was associated with a lower risk for kidney failure (relative risk, 0.32 [95% confidence interval [CI], 0.15-0.67]; P=0.002) and a reduction in proteinuria (weighted mean difference, -0.46 g/d [95% CI, -0.63 to -0.29 g/d]), with no evidence of heterogeneity in these outcomes. Subgroup analysis suggested that the dose modifies the effect of steroids for renal protection (P for heterogeneity=0.030): Relatively high-dose and short-term therapy (prednisone >30 mg/d or high-dose pulse intravenous methylprednisolone with duration ≤1 year) produced significant renal protection, whereas low-dose, long-term steroid use did not. Steroid therapy was associated with a 55% higher risk for adverse events. The quality of included studies was low, however, limiting the generalizability of the results. In conclusion, steroids appear to provide renal protection in patients with IgA nephropathy but increase the risk for adverse events. Reliably defining the efficacy and safety of steroids in IgA nephropathy requires a high-quality trial with a large sample size.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis published in 2012 suggested that there were bene fi ts resulting from the use of corticosteroid therapy, but it was noted that trials included in the meta-analysis were small and of poor quality, with adverse outcomes not fully reported. 27”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [27]
In the citing paper
“A meta-analysis published in 2012 suggested that there were bene fi ts resulting from the use of corticosteroid therapy, but it was noted that trials included in the meta-analysis were small and of poor quality, with adverse outcomes not fully reported. 27”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [27]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Commonest Glomerulonephritis in the World: IgA Nephropathy
(1987) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068143 · Cited by 870
Bias in meta-analysis detected by a simple, graphical
Stuck, A. E., Rubenstein, L. Z., Wieland, D., Vandenbroucke, J. P., Irwig, L., Macaskill, P., Berry, G., Glasziou, P., Seagroatt, V., Stratton, I., et al. (1998) · BMJ · doi:10.1136/bmj.316.7129.469 · Cited by 699
Donadio, J. V., & Grande, J. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020109 · Cited by 661
Remission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
Corticosteroids in IgA nephropathy: a randomised controlled trial
Pozzi, C., Bolasco, P., Fogazzi, G., Andrulli, S., Altieri, P., Ponticelli, C., & Locatelli, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03563-6 · Cited by 532
Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors
D’Amico, G. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.8966 · Cited by 499
Thompson, S. G., & Pocock, S. J. (1991) · The Lancet · doi:10.1016/0140-6736(91)91975-z · Cited by 487
Cited by
Items 101–190 of 190
Clinical practice guidelines for the provision of renal service in Hong Kong: General Nephrology
Tang, S. C. W., Wong, A. K., & Mak, S. (2019) · Nephrology · doi:10.1111/nep.13500 · Cited by 9
Wong, M. G., Lv, J., & Perkovic, V. (2022) · JAMA · doi:10.1001/jama.2022.12712 · Cited by 9
Self-citationCorticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial
Zhang, Y., Hu, Y., Lv, J., & Zhang, H. (2023) · Pediatric Nephrology · doi:10.1007/s00467-023-05919-9 · Cited by 10
Self-citationRivedal, M., Haaskjold, Y. L., Eikrem, Ø., Bjørneklett, R. O., Marti, H., & Knoop, T. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03481-6 · Cited by 9
“Moreover, many studies related to treatment are retrospective, lack statistical significance, or have confounding designs [10, 24, 25].”
BackgroundThe effects of cytotoxic therapy in progressive IgA nephropathy
Shin, J., Lee, J. E., Park, J. H., Lim, S., Jang, H. R., Kwon, G. Y., Huh, W., Jung, S., Kim, Y.-G., Oh, H. Y., et al. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1153805 · Cited by 8
“and varied [32 (10, 58) months] substantially in the study, further studies with a larger sample size are needed to determine whether pathologic classification predicts responsiveness to immunosuppressive treatment (28).”
BackgroundResultImmunosuppressive therapy in patients with IgA nephropathy.
Peters, H., Brand, J., Berger, S. P., & Wetzels, J. F. M. (2015) · PubMed · Cited by 8
Pathophysiologie und Therapie der IgA-Nephropathie
Bollin, R., & Haller, H. G. (2018) · Der Internist · doi:10.1007/s00108-018-0443-0 · Cited by 8
Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents
Chen, J., Xu, H., Peng, Z., Lin, L., Li, C., Zhu, X., & Liu, S. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01795-6 · Cited by 8
An update on corticosteroid treatment for IgA nephropathy
Ghaddar, M., Barratt, J., & Barbour, S. J. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000881 · Cited by 10
Tanaka, S., Ninomiya, T., Katafuchi, R., Masutani, K., Tsuchimoto, A., Tokumoto, M., Hirakata, H., Ooboshi, H., Kitazono, T., & Tsuruya, K. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx223 · Cited by 8
Repurposing of the Herbals as Immune-Boosters in the Prevention and Management of COVID-19: A Review
Kumari, R., Venaik, A., Hasibuzzaman, M. A., Azure, S. A., Ojha, R. P., & Sahi, A. K. (2021) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.15.1.35 · Cited by 8
Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects
Salvadori, M. (2016) · World Journal of Nephrology · doi:10.5527/wjn.v5.i1.6 · Cited by 6
Liu, M., Bian, X., Wang, L., & Li, G. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.922365 · Cited by 7
“A meta-analysis reported that patients with lower proteinuria levels had a lower risk of renal composite endpoints (10).”
BackgroundHirahashi, J., Hanafusa, N., Wada, T., Arita, M., Hishikawa, K., Hayashi, M., & Nangaku, M. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.4623 · Cited by 7
Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria
Zhong, Z., Tang, Y., Tan, J., Tan, L., Pei, G., & Qin, W. (2020) · International Urology and Nephrology · doi:10.1007/s11255-020-02644-2 · Cited by 7
Beck, N., Walz, G., & Schneider, J. (2022) · Kidney360 · doi:10.34067/kid.0006702021 · Cited by 7
Li, Q., Chen, W.-J., Shen, J., Wu, Y. C., Li, R.-X., Zhong, Y., Zeng, R., & Deng, Y. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw015 · Cited by 7
“Currently, immunosuppressive therapy is the major but non-specific option used for treating the severe form of IgAN with proteinuria; however, the outcomes remain controversial (Lv et al., 2012; Boyd et al., 2012).”
BackgroundCorticosteroids for IgA Nephropathy
O'Shaughnessy, M. M., & Lafayette, R. A. (2017) · JAMA · doi:10.1001/jama.2017.9359 · Cited by 7
Fang, J., Wang, M., Zhang, W., & Wang, Y. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1278 · Cited by 6
“Hormones are a major drug type in the treatment of kidney diseases and their anti‑inflammatory, anti‑immunisation and antitoxin effects have been demonstrated previously (28,29).”
Acute Glomerular Diseases in Children
Kher, K. K. (2015) · The Open Urology & Nephrology Journal · doi:10.2174/1874303x015080100104 · Cited by 8
“A recent meta-analysis of published studies of IgA in adults and children demonstrated that corticosteroid use in IgAN was associated with a lower risk of renal disease and proteinuria in the follow up periods [96].”
BackgroundIgA Nephritis with Declining Renal Function
Ponticelli, C. E., & Glassock, R. J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010030 · Cited by 6
Management of IgA nephropathy and the expanding role of immunomodulation
Canetta, P. A., & Reich, H. N. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.002 · Cited by 5
Literature Review: The Efficacy of Glucocorticoids in IgA Nephropathy Patients
Aljebrin, Y. J., Rashed, A. A. B., Alahmed, M. A., Alsamadani, J. H., Mahamat, F. M. A., Alrsheedi, A. S. E., Alshammari, A. M. A., Ghaith, A. M., Alkhathami, I. K., & Alsubaiei, A. M. (2021) · Entomology and Applied Science Letters · doi:10.51847/msqg8ilxvw · Cited by 5
Prasad, A., Patel, P., Kumari, M., Saxena, G., Chakrabarty, D., & Singh, S. S. (2023) · Springer eBooks · doi:10.1007/978-981-99-2824-8_1 · Cited by 5
Ye, Z., Zhang, L., Xu, L., Shi, W., Hu, H., Shi, X., Zhong, W., Hou, S., Yan, H., Zhang, B., et al. (2013) · Nephrology · doi:10.1111/nep.12177 · Cited by 5
“Thus, for high risk IgA nephropathy patients with 24-h urinary protein more than 1 g, probucol may improve proteinuria in the early phases of treatment, but a glucocorticoid may be needed for long-term control of urinary protein.(4,5,25) Although the 24-h urinary protein levels at the 1-year and 2-year follow-ups have…”
ResultGonçalves, C., Monteiro, C. S. D. J., & dos Santos, J. L. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1630 · Cited by 5
“Blood and lymphatic disorders (7) Disseminated intravascular coagulation (1)”
BackgroundEfficacy and safety of rituximab in primary IgA nephropathy: a retrospective study
Li, J., Nie, Z., Li, G., & Bao, B. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02617-0 · Cited by 4
“Several studies have demonstrated that glucocorticoids (GCs) prevent deterioration of renal function without remarkable side effects [4, 5].”
Emerging perspectives in the management of IgA nephropathy: a comprehensive review
Gomes, A. M., Schau, B., & Farinha, A. (2024) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000264 · Cited by 6
“81 Unfortunately, the study also concluded that steroid therapy was associated with 55% higher risk of adverse events.”
InfluentialPersonalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases
Gluba-Brzózka, A., Franczyk, B., Olszewski, R., Banach, M., & Rysz, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061248 · Cited by 5
“A low protein diet [39], RAAS blockade, non-steroidal anti-inflammatory drugs [40] and corticosteroids [41] are used to lower blood pressure, decrease albuminuria, provide renoprotection and slow progression to ESRD.”
BackgroundChronic Allograft Injury: An Overview of Pathogenesis and Treatment Strategies
Madariaga, H. M., & Riella, L. V. (2017) · Contributions to nephrology · doi:10.1159/000468963 · Cited by 5
Das, P. K., Chaudhury, A. R., Dasgupta, S., Bhattacharya, K., Pal, A., Sircar, D., & Sen, D. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101166 · Cited by 5
“11 12-14 Tarpeyo, a targeted release preparation of budesonide released in the intestine, was found to have a salutary effect in short-term reduction of proteinuria and protection of GFR. 15 In India, we had controlled-release (CR) enteric-coated budesonide preparation available at a relatively low…”
Chen, J., Liu, S., Xu, H., Wang, W., Xie, Y., Tang, W., Yuan, Q., Zheng, L., Lin, L., Fu, S., et al. (2020) · Medical Science Monitor · doi:10.12659/msm.922839 · Cited by 5
Yamatani, S., Kono, K., Fujii, H., Hirabayashi, K., Shimizu, M., Watanabe, K., Goto, S., & Nishi, S. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02791-x · Cited by 3
“In addition, several meta-analyses demonstrated that SP therapy could halt the progression of kidney dysfunction [20].”
BackgroundFloege, J. (2024) · Die Urologie · doi:10.1007/s00120-023-02268-1 · Cited by 3
Ali, S. N., Fusco, N., Makhija, D. U., Diaby, V., Oladapo, T., Devani, D., Pinto, C. S., Mathur, M., & Fernandes, A. W. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04155-7 · Cited by 3
Pharmacological, Therapeutic, and Immunomodulatory Role of Tinospora cordifolia
Rajak, N., Kavita, B. S. P., Kumar, P., Singh, S., & Garg, N. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815123289123010010 · Cited by 3
Nagy, J., Sági, B., Máté, J., Vas, T., & Kovács, T. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30924 · Cited by 3
Review of cases of IgA nephropathy
WORLD, M. J. (2013) · Journal of the Royal Army Medical Corps · doi:10.1136/jramc-2013-000072 · Cited by 3
IgA Nephropathy: Clinical Features, Pathogenesis, and Treatment
Appel, G. B. (2019) · Springer eBooks · doi:10.1007/978-3-319-49379-4_20 · Cited by 3
Singh, J., Singh, A., Sharma, V., Singh, T. D., Singh, M., Garg, R., Sharma, R., & Gautam, D. N. S. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-022-00300-0 · Cited by 6
Core Concepts in Hypertension in Kidney Disease
Agarwal, R., & Singh, A. K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9 · Cited by 4
Oruç, A., Şumnu, A., Türkmen, A., Baştürk, T., Cebeci, E., Turgutalp, K., Çetinkaya, H., Kibar, M. Ü., Seyahi, N., Tatar, E., et al. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2341787 · Cited by 2
ANTI ARTHRITIC ACTIVITY OF TINOSPORA CORDIFOLIA LEAVES BY DENATURATION STUDIES
Ramya, R. (2016) · International Journal of Innovative Research in Medical Science · doi:10.23958/ijirms/vol01-i01/02 · Cited by 4
Floege, J. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01588-w · Cited by 2
Yang, X., Ma, F., Bai, M., Wang, Y., Jia, Q., Dong, R., Liu, C., & Sun, S. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1956536 · Cited by 2
“in a number of validation studies that only included patients with preserved kidney function [9,14].”
BackgroundApproach to the Patient with Chronic Glomerular Disease
Cohen, S. D., & Appel, G. B. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00037-8 · Cited by 2
Ruan, Y., Chen, W., Li, Z., Tang, X., Li, J., Yu, X., & Yang, Q. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.50965 · Cited by 2
Corticosteroids Should Be Used To Treat Slowly Progressive IgA Nephropathy: PRO
Cunningham, A. M., & Reich, H. N. (2021) · Kidney360 · doi:10.34067/kid.0007192020 · Cited by 2
Wang, Z., Qu, Y., Zhang, Y., Zhu, X. Y., Gong, X. W., & Chen, H. Y. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/2484626 · Cited by 2
“Glucocorticoids easily enter cells through cell membranes and combine with intracellular receptors, thus playing important physiological and pharmacological roles [18].”
BackgroundRetractedTonsillectomy Monotherapy for IgA Nephropathy: A Case Series
Marumoto, H., Tsuboi, N., Kawamura, T., & Yokoo, T. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.07.002 · Cited by 1
The Treatment of Primary IgA Nephropathy
Song, D. (2013) · Journal of Nephrology & Therapeutics · doi:10.4172/2161-0959.1000144 · Cited by 1
“The risk for adverse events increases in IgAN patients with steroid therapy, so the safety needs high-quality trial with a large sample size [12].”
BackgroundDrug-Induced Hypertension in Chronic Kidney Disease
Vichot, A. A., & Perazella, M. A. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9_12 · Cited by 1
Komissarov, K. S., Pilotovich, V., & Minchenko, E. I. (2020) · Рецепт · doi:10.34883/pi.2020.23.4.002 · Cited by 1
Gould, E. R., & Burgner, A. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3286-3_12 · Cited by 1
IgA Nephropathy - Clinical Features, Pathogenesis, and Treatment
Appel, G. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-27334-1_20-1 · Cited by 1
Efficacy of combination therapy for childhood complicated focal IgA nephropathy
Aoto, Y., Ninchoji, T., Kaito, H., Shima, Y., Fujimura, J., Kamiyoshi, N., Ishimori, S., Nakanishi, K., Minamikawa, S., Ishiko, S., et al. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02190-4 · Cited by 1
“Approximately 15–50% of children with diffuse IgAN continue to present with proteinuria after receiving 2-year combination therapy [9, 14, 24] and may develop ESKD in the future [20, 23, 25, 26].”
BackgroundLai, K. N., & Tang, S. C. W. (2015) · doi:10.1093/med/9780199592548.003.0068_update_001 · Cited by 1
Kagne, S. S. (2023) · International Journal of Pharmacognosy & Chinese Medicine · doi:10.23880/ipcm-16000235 · Cited by 1
Billot, L., Monaghan, H., Wong, M. G., & Perkovic, V. (2021) · doi:10.31219/osf.io/d7qrw · Cited by 1
Self-citationCorticosteroids in Patients With IgA Nephropathy: Is the Lower the Better?
Rauen, T., Vogt, K., & Seikrit, C. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.05.031 · Cited by 1
Mesangiopathies: IgA Nephropathy
Nast, C. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05405-8
Optimal use of corticosteroids in nephrology
Sprangers, B. (2014) · Journal of Translational Internal Medicine · doi:10.4103/2224-4018.135602
“GLOMERULAR DISEASES Glomerular diseases are the third most common cause of end stage renal disease (ESRD) in western countries with incidence ranging between 10% and 20% in patients with ESRD.”
BackgroundUpdate on the management of IgA nephropathy
Tiwari, J. P. (2014) · Clinical Queries Nephrology · doi:10.1016/j.cqn.2014.11.001
Cytokine gene polymorphisms: Can these differentiate renal disease entities?
Lim, C. S. (2012) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2012.10.001
“The differentiation between IgAN and TBMN is quite important because of their different clinical courses and approaches to treatment [1,12].”
Background[The most frequent childhood vasculitides].
Harjaček, M. (2013) · PubMed
MEDICINAL PROPERTIES AND GENETIC DIVERSITY OF A MAGICAL SHRUB TINOSPORA CARDIFOLIA: AN UPDATE
Kulshrestha, S. (2015) · International Journal of Pharma and Bio Sciences
The Implication of the KDIGO Clinical Practice Guidelines on Management of IgA Nephropathy
Li, P. K., & Chow, K. M. (2016) · Springer eBooks · doi:10.1007/978-4-431-55588-9_14
Non-infectious aortitis in an immunosuppressed renal transplant recipient with IgA nephropathy
Snead, C. M., Crockett, S. C., & Bailey, P. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221136
IgA Nephropathy and Henoch Schönlein Nephritis, Pediatric
Kakajiwala, A. K., & Meyers, K. E. C. (2019) · Springer eBooks · doi:10.1007/978-3-319-49379-4_21
Update in Pediatric Nephrology
Weidemann, D. K., & Bitzan, M. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-58027-2_15 · Cited by 1
Some opportunities of using xanthine oxidase inhibitors
Zhelyabina, O. V., & Елисеев, М. С. (2019) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2019-1-114-120
T.cordifolia: A medicinal plant
Rawat, H., Sharma, M., & Sharma, S. (2020) · International Journal of Chemical Studies · doi:10.22271/chemi.2020.v8.i4a.9855
Rocha, H. (1946) · Archivos de la Sociedad Oftalmológica Hispano-Americana
IgA Nephropathy and Henoch Schönlein Nephritis, Pediatric
Kakajiwala, A. K., & Meyers, K. E. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-27334-1_21-1
Oates, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-97220-6_7 · Cited by 1
Approach to the Patient with Chronic Glomerular Disease
Cohen, S. D., & Appel, G. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00045-0
(2021) · Reactions Weekly · doi:10.1007/s40278-021-89186-5
Tinospora cordifolia (Giloy) a medicinal plant
Goswami, A., Chaudhary, S., Shubhkamna, Malik, A., & Malik, M. (2020) · Annals of Horticulture · doi:10.5958/0976-4623.2020.00025.0
IgA Nephropathy in Adults and Children
Yeo, S. C., Trimachi, H., & Barratt, J. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch17 · Cited by 1
Alom, S., Kalita, D., Ahmed, J., Rahman, K., Boruah, M., Sarmah, M., Das, N., & Ali, F. (2022) · Asian Journal of Chemistry · doi:10.14233/ajchem.2022.23970
Takiguchi, R., Nishi, S., Goto, S., & Fujii, H. (2023) · PubMed Central · doi:10.24546/0100481852
Minimal change disease associated with IgA nephropathy “a rare clinical spectrum”: Case report
Serna–Trejos, J. S., Neira–Ruiz, L. C., Bermúdez–Moyano, S. G., Hurtado-Leiton, J. A., & Sánchez, D. A. G. (2023) · International Journal of Medical and Surgical Sciences · doi:10.32457/ijmss.v10i3.2212
Update in Pediatric Nephrology
Weidemann, D. K., & Bitzan, M. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-41542-5_21
Tinospora cordifolia: The Miracle plant
Singh, G. K. (2024) · International Journal of Herbal Medicine · doi:10.22271/flora.2024.v12.i1a.917
TENOSPORA CORDIFOLIA: PHYTOCHEMICAL and PHARMACOLOGICAL REVIEW
Yadav, H., Singh, S. P., Morya, N., & Singh, S. P. (2023) · International Journal of Pharma Professional’s Research (IJPPR) · doi:10.48165/ijppronline.2023.14116
Qin, H., Liu, X., & Chen, J. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04688-x · Cited by 1
“In the past, a meta-analysis indicated that long-term use of corticosteroids glucocorticoids and immunosuppressive drugs increases the risk of systemic infections and other severe adverse events, such as higher morbidity and mortality [11, 12].”
Rivedal, M., Haaskjold, Y. L., Eikrem, Ø., Bjørneklett, R., Marti, H. P., & Knoop, T. (2024) · Figshare · doi:10.6084/m9.figshare.26674308
Haseeb, M. E., Mohammed, H. E. M., Heiba, A. A., Hanen, G., Elaziz, N. A. O. A., & Nasser, M. (2026) · ASIDE Internal Medicine · doi:10.71079/aside.im.012726340
Treatment and practical considerations of IgA nephropathy
Sawaf, H., Kim, J., Mehdi, A., Cavanaugh, C. J., & Taliercio, J. J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1911077
“Until the advent of new therapies, systemic glucocorticoids had been the mainstay immunosuppressive option for IgA nephropathy however they came with deleterious side effects (85).”
Metadata
- Authors
- Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H.
- Affiliations
- Peking University (CN)
- The University of Sydney (AU)
- The University of Queensland (AU)
- University of British Columbia (CA)
- Corresponding author
- Lv, Jicheng
- Xu, Damin
- Ma, Xinxin
- Zhang, Hong
- Wang, Haiyan
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2012-06
- Volume
- 23
- Issue
- 6
- Pages
- 1108-1116
- ISSN
- 1046-6673 (ISSN-L)
- PMC
- PMC3358763
- OpenAlex
- W2107238505
- Cited by
- 190
- References
- 33
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 12 · 2021: 13 · 2020: 13 · 2019: 13 · 2018: 16 · 2017: 24 · 2016: 22 · 2015: 16 · 2014: 13 · 2013: 13 · 2012: 2
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- IgA nephropathy, corticosteroid therapy, prednisone, methylprednisolone pulse therapy, proteinuria, renal failure, renal protection, adverse events
- MeSH terms
- Administration, Oral, Adrenal Cortex Hormones, China, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glomerulonephritis, IGA, Humans, Infusions, Intravenous, Kidney Failure, Chronic, Kidney Function Tests, Male, Methylprednisolone, Prednisone, Prognosis, Severity of Illness Index, Survival Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Disease-Free Survival, Pulse Therapy, Drug
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.